Hair Cloning: Why Cell Therapy Keeps Being “Two Years Away”
Published by AmpleLab Research
Hair cloning is the most durable promise in hair loss: take a few of your own follicles, multiply them in a lab, and put back thousands. It has been “a few years away” for as long as companies have been testing it in people. This article follows what has been tried in patients, what the newer stem cell programmes have shown so far, and why the gap between a follicle growing in a dish and hair on a head keeps proving wider than the announcements suggest.
The short version of the record is that nothing in this field is an approved, proven treatment. Since the late 2000s, several groups have tested cultured follicular cells in people. None has produced an approved treatment, and the strongest published randomised evidence showed a temporary benefit at only one of three tested doses. The newer wave, built on stem cells and engineered follicle germs, is mostly mouse data and company announcements. And “cloning” is not quite the right word for any of it.
“Cloning” Is the Wrong Word, but It’s the One People Search
No one is copying a person. Two quite different strategies sit under the label. The first, usually called hair multiplication, takes a few follicles from the back of the scalp, grows the cells that instruct a follicle to build a hair (the dermal papilla or the closely related dermal sheath), and injects them into thinning areas, hoping they coax new or shrunken follicles into producing proper hairs. The second is follicle engineering: assembling a new follicle from its component cells in the lab, from adult cells or from induced pluripotent stem cells (iPSCs, adult cells reprogrammed into an embryonic-like state), and implanting it.
Both depend on the same biology. The dermal papilla is the signalling centre of the follicle, and in animal experiments it can induce follicles to form. Whether cultured human cells can still do that job is where the field first runs into trouble.
The Bottleneck: Cultured Cells Forget What They Are
Dermal papilla cells from rodents can induce new follicles, but cultured human ones had repeatedly failed to. This study grafted human cells between separated neonatal foreskin epidermis and dermis on immunodeficient mice. Intact human papillae induced follicles; cells grown in conventional flat culture from two donors produced none, and gene expression shifted most between intact papillae and the earliest outgrowths, with Wnt signalling genes falling. Growing the cells as three-dimensional spheroids restored induction in five of seven donors, at efficiencies ranging from 10% to 60%. The authors list the limits themselves: two cell lines failed, induced follicles were often small and frequently did not produce a fibre that emerged from the skin, they lacked sebaceous glands, and grafts were followed for six weeks at most. It is a preclinical xenograft study with a small number of donors.
That 2013 paper is the cleanest statement of the problem every programme below has had to solve. The cells you can easily grow in quantity are not the cells that build a follicle, and getting that ability back is partial, donor-dependent and not yet shown to last.
The First Wave: Three Programmes That Reached Patients
Unlike most pipeline stories, this field has a human trial history. It just doesn't have a product.
Intercytex (UK). Intercytex injected patients' own cultured dermal papilla cells back into the scalp. Its Phase II trial enrolled 19 people and 13 completed 48 weeks of follow-up; in March 2009 the company announced an increase in hair count in the majority of evaluable subjects. The investigator, Dr Bessam Farjo, reports that the UK trial was abandoned that year, mainly for financial reasons. The investigator's own write-up cautions that the sample was small.
Aderans (Japan). Aderans, the parent company of Bosley, ran its own cell therapy programme through a research institute. Its 2024 announcements describe a UK Phase 1 in which cultured cells were injected into 33 participants and 10 showed some effect, and a US Phase 2 in about 450 people with early to mid-stage androgenetic alopecia (AGA). The company describes initial data as suggesting a single dose can produce durable growth, but no outcome figures were published, and the announcement exists to hand the programme to a start-up that would “resume” it.
Stemson received exclusive global rights to Aderans' cell therapy technology. The release says Aderans ran Phase 2 testing in 445 men and women with early to mid-stage AGA, that preliminary data suggest a single dose can “safely produce long lasting and durable hair growth,” and that Stemson will resume the Phase 2 programme and combine it with its own iPSC work. It reports no outcome figures, endpoints or publication, gives no dates for human trials, and describes Stemson itself as pre-clinical. These are company statements, not independently verified data.
RepliCel and Shiseido. RepliCel's RCH-01 uses cells from the dermal sheath cup, the lower end of the follicle's connective tissue sheath. Shiseido, which held the Asian licence, funded the one randomised trial published so far.
A randomised, placebo-controlled, double-blind dose-finding study in 50 men and 15 women aged 33 to 64 with pattern hair loss. Cells from occipital follicles were cultured and injected once, at 7.5 × 106, 1.5 × 106 or 3.0 × 105 cells or placebo, in four separate scalp regions, with hair density and diameter measured to 12 months. Only the lowest dose beat placebo on total hair density and cumulative hair diameter, at 6 and 9 months; the authors describe the effect as temporary, lasting until 9 months, and note that lower doses were not tested. Men and women improved similarly and no serious adverse events were reported. The study was funded by Shiseido. RepliCel's own release adds that the authors did not express efficacy as a percentage increase.
The relationship then broke down. RepliCel terminated the licence in December 2021, calling it a step in resolving a dispute, and in October 2023 the arbitration tribunal dismissed RepliCel's claims and found that Shiseido had validly terminated their Collaboration and Technology Transfer Agreement. RepliCel said management was considering the impact. A November 2022 RepliCel update referred to a third RCH-01 study funded under the Shiseido licence; we found no published results from it.
Why Each One Stalled: Three Patterns in the Record
These programmes differ in method, so it would be wrong to read one failure across all of them. But a few features recur, and they explain why a hopeful headline in this field has so far not turned into a treatment. This is our reading of the published record, not a finding any of the papers states.
The effect has been small, temporary or hard to size
In the strongest published randomised trial only one of three doses worked, the benefit faded by 12 months, and dose-response ran the wrong way: more cells did not mean more hair. Intercytex and Aderans reported company-framed positives without published effect sizes.
The cells behave differently in a dish
Cultured human dermal papilla cells lose the ability that makes them useful, and the 3D fix restored it unevenly across donors. That is a manufacturing and consistency problem as much as a biology one.
Most programmes ended with a money or licensing event
Intercytex abandoned its UK trial for financial reasons, Aderans handed its programme to a start-up, Stemson shut down after failing to raise funds, and RepliCel lost its partner in arbitration. That pattern may reflect how hard it is to finance a long, uncertain cell therapy programme, but it is not proof that money was the only obstacle.
The Second Wave: Better Cells, Same Distance From Patients
The newer programmes try to bypass the culture problem by building follicles from stem cells or from carefully assembled cell mixtures. The results are credible science. They are also, so far, in mice or in the lab.
Stemson Therapeutics (US). Founded in 2018 on work from Alexey Terskikh's lab at Sanford Burnham Prebys, Stemson used human iPSC-derived dermal papilla cells. The 2019 work combined them with mouse epithelial cells on a biodegradable scaffold in nude mice, and the lab itself noted the follicles were not yet fully human. In February 2024 the company announced hair growth from an all-human cell product in humanised mice, supported by an image of a graft ten weeks after transplant; no sample sizes, quantitative outcomes or peer-reviewed publication accompanied it. In January 2025 Endpoints News reported that Stemson had shut down after failing to secure new investment.
Yunce Medical (China). Yunce, based in Chengdu, has described an iPSC-derived hair follicle programme in conference presentations. We could not find peer-reviewed data or a registered human trial for it.
OrganTech and the RIKEN group (Japan). Takashi Tsuji's group reported in 2016 that iPS cells derived from mouse gum tissue, shaped into embryoid bodies and implanted in immune-deficient mice, formed skin-like tissue with hair follicles and sebaceous glands connecting to nerve and muscle. In 2026 the group published a paper in Biochemical and Biophysical Research Communications on regenerating mouse hair follicles in culture. The recipe combines epithelial stem cells from the bulge of adult mouse whisker follicles, cultured dermal papilla cells, and a third population of PDGFRα+/Sca1+/CD34-high mesenchymal cells, which the authors isolated from the subcutaneous layer of hairy skin and from around the bulge. Without that third population the cultured follicles formed bulbs only; with it, they grew downward and produced hair shafts. The in vitro comparisons used roughly 20 to 100 follicle germs per condition, read out at 17 days. In a 3D skin equivalent the follicles cycled through growth and regression phases of about 9 and 6 days (five follicles), and a graft containing them, transplanted onto mice, kept producing hair for more than 68 days with host nerve fibres and arrector pili muscle connections.
Every cell in that paper is mouse tissue, and a mouse hair cycle in this system lasts days where a human one lasts years. The authors name humanised models as a future step. The work was funded in part by OrganTech, one author was an OrganTech director during the study, the work was partly done under an invention agreement between RIKEN and the company, and Tsuji declares a pending patent linked to OrganTech. The company has said it is pursuing a staged clinical translation strategy. No human trial has been announced.
Yokohama National University and KISTEC (Japan). In 2022 a Japanese team described “follicloids,” organoids that grow hair shafts in culture at close to 100% efficiency, reaching about 3 mm, and that cycled through repeated hair replacement after transplant into mice. They were built from embryonic mouse cells, and the authors say the system must be optimised with human cells, which are difficult to culture.
Human Testing Now: Epibiotech and HairClone
Two cell-injection programmes are now being tested in people. They sit at different points on the evidence ladder, and the difference matters more than the headlines suggest.
Epibiotech (South Korea). Evidence level: registered human trial, no results yet. Epibiotech is testing EPI-001, an autologous dermal papilla cell therapy for androgenetic alopecia, in a Phase 1/2a study registered as NCT07618195. Cells are taken from the patient’s own follicles at the back of the scalp, cultured, and injected into the thinning area. The registry describes a single-site study at Chung-Ang University Hospital in Seoul, enrolling adults of either sex, with 42 participants planned and industry funding from Epibiotech.
The design has two parts. Phase I is a standard 3+3 dose-escalation to find the maximum tolerated dose and a recommended Phase 2 dose, with participants followed for up to 24 weeks. Phase IIa then randomises participants 2:1 to EPI-001 or placebo, double-masked, with follow-up to 48 weeks. The registered primary outcome is dose-limiting toxicity within four weeks of administration. Hair outcomes, including phototrichogram hair count and diameter, investigator and expert-panel photo ratings and participant self-assessment, are all listed as secondary outcomes, so the registry does not define a primary efficacy endpoint. The registered primary completion date is June 2028, and no results have been posted.
The timeline is worth reading carefully. The registry gives a start date of 12 January 2026 and first posted the entry on 1 June 2026. The company reported dosing its first patient on 21 April 2026, and in June said the study had moved from its first, lower-dose cohort to the second after a safety review, with plans to begin Phase 2a enrolment within 2026. That makes this registered formal testing, not evidence that the therapy works.
HairClone (UK, treating patients in Guatemala). Evidence level: company-reported clinical testing, no public protocol. HairClone is a company with a UK research facility that offers follicle banking and is developing a cell injection therapy for pattern hair loss.
The company says it has built a GMP cell manufacturing laboratory in a private hospital in Guatemala City, below the Schambach Hair Clinic, where patients' own follicle cells will be injected, and that its culture system was transferred from its UK research facility and validated. The announcement says the first set of volunteers has been selected, that Guatemala regulates autologous cell therapies like transplants, and that efficacy will be monitored through visual improvement, quantified growth changes and cellular mechanisms. It names no ethics committee, registry entry, protocol, participant number or results.
Later statements add a little detail but not a dataset anyone can assess. HairClone’s 30 September 2026 update, posted about a new clinical partner, says the company has begun injecting cells grown from banked follicle tissue into an early cohort of patients and that its clinical lead would present preliminary results at the ISHRS World Congress, which ran from 15 to 17 October. In August, a US hair surgeon affiliated with HairClone was quoted from her newsletter saying the first three patients had returned for follow-up with positive regrowth. The company’s chief executive had also told a hair loss blog that the congress presentation would cover the first eight patients at 12 weeks. As of 25 October, none of these statements has been accompanied by a public presentation or underlying dataset that we have seen. Until the measurements, patient-level results and methodology can be assessed, these reports should not be treated as independent evidence of efficacy. The description of Guatemala’s regulatory framework also comes from the company.
Early autologous cell therapies are sometimes tested this way, so the setting is not in itself a red flag. It does mean the two programmes should not be read as equals: Epibiotech has a registered design with a placebo stage to come, while HairClone has patients and encouraging remarks but no endpoint, comparison group or data to read. Follicle banking is offered now, ahead of any published efficacy evidence. For readers, the fair position is interest in what each eventually publishes and no more than that until it does.
How to Read the Next “Breakthrough”
Almost every claim in this field can be sorted with a handful of questions. They are worth asking of any headline, including the ones in this article.
Whose cells, and from what species?
Mouse cells in mouse skin is a different claim from human cells in human skin. Several of the most-quoted results above are mouse cells.
A dish, a mouse or a head?
Hair shafts growing in culture at near-100% efficiency says the organoid works. It does not say hair will grow on a scalp.
How many hairs, how thick, for how long?
The human trials above reported hair density or counts at fixed time points and one showed the benefit fading. “New hair growth” without size and duration is not a result.
Is there a registered trial and a publication?
A registry entry, a protocol and a peer-reviewed paper let outsiders check the claim. A press release or conference slide does not.
Who paid, and who is speaking?
Most statements here come from the sponsoring companies. That is not disqualifying, but it is why they are labelled as company statements throughout.
Frequently Asked Questions
Is hair cloning available yet?
No. As far as we could find, no cell-based hair multiplication therapy is approved or available as a proven treatment. The programmes in this article are in trials, in animal studies, or in early company testing, and the one published randomised trial showed a temporary effect at a single dose.
Why is hair cloning always “two years away”?
Cultured human dermal papilla cells lose the ability to induce follicles, restoring it works unevenly between donors, and the human trials so far have shown small or temporary effects. Several programmes also ended with funding or licensing problems. Each new announcement tends to solve one step, usually in mice or in a dish, while the later steps remain open.
Is hair cloning the same as a hair transplant?
No. A transplant moves existing follicles from the back of the scalp to thinning areas, so the total number of follicles stays the same. Cell therapies aim to create more hair-producing units from a small starting sample. The limited-donor-hair problem that motivates cloning is also the target of other research, including verteporfin.
Will it work for advanced baldness or for women?
That has not been shown. The Shiseido-funded trial included 15 women and found men and women improved similarly at the one effective dose, but it was small and temporary. None of the newer iPSC or organ germ approaches has been tested in people yet.
How is this different from other new hair loss drugs?
Cell therapies aim to make new follicles or rebuild failing ones, while most drug candidates try to wake or protect the follicles that remain. Our pipeline tracker covers the drug candidates, and our article on ET-02 covers one that targets follicle stem cells.
Selected Research
Status checked on 25 October 2026. Much of the human-trial information in this field is company-reported and has not been peer reviewed, so we will update this article when new trial data are published.
This article is provided for educational purposes and does not constitute medical advice. The cell therapies described are investigational and none is approved as a proven treatment for hair loss. AmpleLab products are cosmetic formulations, unrelated to the therapies discussed, and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.